Original Source(s)
Related Content
Does Timing Matter in Gene Therapy for nAMD?
Carl C. Awh, MD, FASRS, discusses 2-year phase 2b PRISM results showing durable outcomes with investigational 4D-150 in patients with recently diagnosed neovascular age-related macular degeneration.
July 15, 2026
-
2 min
Endogenous Endophthalmitis and Missed Diagnoses
Retrospective study describes how endogenous endophthalmitis often presents without systemic symptoms
July 21, 2026
-
3 min